Home » Stocks » ImmuCell

ImmuCell Corporation (ICCC)

Stock Price: $5.70 USD 0.18 (3.26%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 41.11M
Revenue (ttm) 14.22M
Net Income (ttm) -1.56M
Shares Out 7.21M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $5.70
Previous Close $5.52
Change ($) 0.18
Change (%) 3.26%
Day's Open 5.43
Day's Range 5.50 - 5.70
Day's Volume 5,045
52-Week Range 3.70 - 8.13

More Stats

Market Cap 41.11M
Enterprise Value 42.58M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 7.21M
Float 5.16M
EPS (basic) -0.22
EPS (diluted) -0.22
FCF / Share -0.22
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14,934
Short Ratio 0.65
Short % of Float 0.85%
Beta 1.42
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.89
PB Ratio 1.40
Revenue 14.22M
Operating Income -1.02M
Net Income -1.56M
Free Cash Flow -1.58M
Net Cash -1.47M
Net Cash / Share -0.20
Gross Margin 47.39%
Operating Margin -7.19%
Profit Margin -11.00%
FCF Margin -11.14%
ROA -1.59%
ROE -5.28%
ROIC -3.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.00*
Low
14.0
Current: $5.70
High
14.0
Target: 14.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue13.7210.9910.439.5410.237.606.015.395.114.39
Revenue Growth24.91%5.32%9.3%-6.69%34.64%26.46%11.45%5.45%16.53%-
Gross Profit6.745.195.225.426.254.453.063.052.812.30
Operating Income-0.95-1.45-0.240.892.12-0.21-0.020.25-0.63-0.69
Net Income-1.30-2.32-0.170.511.21-0.170.120.09-0.41-0.38
Shares Outstanding6.825.494.954.233.043.033.023.022.982.97
Earnings Per Share-0.19-0.42-0.030.120.38-0.060.040.03-0.14-0.13
EPS Growth----68.42%--33.33%---
Operating Cash Flow0.23-0.371.18-0.222.900.301.100.34-0.04-0.81
Capital Expenditures-0.94-1.78-17.71-3.56-2.65-1.54-0.60-0.28-0.24-0.12
Free Cash Flow-0.71-2.15-16.54-3.780.25-1.230.500.07-0.28-0.93
Cash & Equivalents8.772.523.8010.626.043.345.264.914.964.63
Total Debt8.429.778.963.013.190.901.091.271.440.99
Net Cash / Debt0.35-7.24-5.167.612.862.444.173.653.523.64
Assets38.6932.7334.3024.7014.5411.0510.9611.0310.9910.75
Liabilities9.7010.9910.704.983.931.791.561.841.971.47
Book Value28.9921.7423.5919.7210.619.269.409.199.029.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ImmuCell Corporation
Country United States
Employees 48
CEO Michael F. Brigham

Stock Information

Ticker Symbol ICCC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ICCC
IPO Date April 30, 1987

Description

ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.